|Photofrin brought to commercialization by Canadian Co. QLT with cancer applications, bladder cancer being one of them but main thrust was Macular degeneration in the eye, that was 1989-1995. Not up to speed on all the company changes since then.QLT Was a market darling for quite a while. At that time laser light could only penetrate 1 cm, limiting the possible response to the PDC drug by depth of target. The new TLT therapeutic laser has achieved 10 CM Light penetration and recent results indicate their PDC is far more active than the current FDA approved PDCs |
Theralase PDC was found to be 668,000 times more effective than ALA and 198 times more effective than Photofrin, two currently approved FDA photoactive drugs."
After 25 years it makes sense that we may be seeing progress in the development of PDCs